- Home
- HOV vs ANAB Comparison
HOV vs ANAB Comparison
Compare HOV & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOV
- ANAB
- Stock Information
- Founded
- HOV 1959
- ANAB 2005
- Country
- HOV United States
- ANAB United States
- Employees
- HOV N/A
- ANAB N/A
- Industry
- HOV Homebuilding
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- HOV Consumer Discretionary
- ANAB Health Care
- Exchange
- HOV Nasdaq
- ANAB Nasdaq
- Market Cap
- HOV 843.6M
- ANAB 759.5M
- IPO Year
- HOV N/A
- ANAB 2017
- Fundamental
- Price
- HOV $101.19
- ANAB $18.46
- Analyst Decision
- HOV Sell
- ANAB Buy
- Analyst Count
- HOV 2
- ANAB 10
- Target Price
- HOV $155.00
- ANAB $36.38
- AVG Volume (30 Days)
- HOV 70.5K
- ANAB 917.7K
- Earning Date
- HOV 05-21-2025
- ANAB 05-08-2025
- Dividend Yield
- HOV N/A
- ANAB N/A
- EPS Growth
- HOV 18.84
- ANAB N/A
- EPS
- HOV 32.36
- ANAB N/A
- Revenue
- HOV $3,084,345,000.00
- ANAB $91,280,000.00
- Revenue This Year
- HOV N/A
- ANAB N/A
- Revenue Next Year
- HOV $5.54
- ANAB $70.85
- P/E Ratio
- HOV $3.29
- ANAB N/A
- Revenue Growth
- HOV 8.80
- ANAB 432.03
- 52 Week Low
- HOV $93.81
- ANAB $12.21
- 52 Week High
- HOV $240.34
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- HOV 29.93
- ANAB 57.40
- Support Level
- HOV $100.88
- ANAB $17.67
- Resistance Level
- HOV $106.80
- ANAB $19.82
- Average True Range (ATR)
- HOV 4.43
- ANAB 1.36
- MACD
- HOV -0.89
- ANAB 0.14
- Stochastic Oscillator
- HOV 6.80
- ANAB 66.20
About HOV Hovnanian Enterprises Inc.
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).